the dips are a buying opportunity for those not already in. I think there is a lot more to this stock, as it is ahead of other companies in CBD and there are more trials going on and many more uses esp. with the opioid crisis.
The % of population able to use the drug will be much higher than you think. Based on the presentation yesterday, 30% of patients haven’t found a drug that works for their seizures, this drug will be added on for epilepsy patients outside those just with LGS and Dravet. IMO. If it works for seizures in those two, it will work for those same seizures in other epilepsies.
Market Data 
Markets 
AI
